https://orcid.org/0000-0002-9647-0853
Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Bartłomiej Pochwat, Anna Julia Krupa, Marcin Siwek & Bernadeta Szewczyk. (2022) New investigational agents for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs 31:10, pages 1053-1066.
Read now
Read now
Michele Fornaro, Assunta Trinchillo, Francesco Saccà, Felice Iasevoli, Maria Nolano & Andrea de Bartolomeis. (2022) Pharmacotherapy to prevent the onset of depression following traumatic brain injury. Expert Opinion on Pharmacotherapy 23:2, pages 255-262.
Read now
Read now
Tom Denee, Timothy Ming, John Waller, Tom Bailey, Olivera Rajkovic-Hooley, Chloe Middleton-Dalby, Hoa H. Le, Qiaoyi Zhang, Paul McCrone & David Taylor. (2021) A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. Current Medical Research and Opinion 37:2, pages 311-319.
Read now
Read now
Laura Orsolini, Domenico De Berardis & Umberto Volpe. (2020) Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opinion on Drug Safety 19:8, pages 981-998.
Read now
Read now
Articles from other publishers (21)
Ying Jiang, Lingyun Zhou, Yuan Shen, Qin Zhou, Yingying Ji & Haohao Zhu. (2024) Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. Journal of Affective Disorders 346, pages 223-229.
Crossref
Crossref
Gloria M. Munayco Maldonado & Thomas L. Schwartz. (2024) Differentiating the third generation of antipsychotics: a focus on lumateperone’s similarities and differences. International Clinical Psychopharmacology 39:1, pages 4-16.
Crossref
Crossref
Lin Cheng, Fan Xia, Ziyan Li, Chenglong Shen, Zhiqian Yang, Hanlin Hou, Suyue Sun, Yuying Feng, Xihao Yong, Xiaowen Tian, Hongxi Qin, Wei Yan & Zhenhua Shao. (2023) Structure, function and drug discovery of GPCR signaling. Molecular Biomedicine 4:1.
Crossref
Crossref
Ting Li, Xiaojie Liu, Xiaoyi Long, Yangyou Li, Jin Xiang, Yuanxia Lv, Xiaoyang Zhao, Shaoqing Shi & Wei Chen. (2023) Brexpiprazole suppresses cell proliferation and de novo lipogenesis through AMPK/SREBP1 pathway in colorectal cancer. Environmental Toxicology.
Crossref
Crossref
Alankar Shrivastava, Ashu Mittal, Rakhi Khabiya, GP Choudhary & Gajanan N. Darwhekar. (2022) Characteristics, Biological Activities, Synthesis, and Methods for the
Determination of Brexpiprazole in Different Matrices. Current Pharmaceutical Analysis 18:8, pages 765-776.
Crossref
Crossref
I. V. Oleichik, T. I. Shishkovskaya, P. A. Baranov & I. Yu. Nikiforova. (2022) Features of Clinical Use of Brexpiprazole, the New Atypical Antipsychotic of the Third Generation: Experience and Perspectives. Psikhiatriya 20:3, pages 134-142.
Crossref
Crossref
Joanne S Carpenter, Natalia Zmicerevska, Jacob J Crouse, Alissa Nichles, Alexandra Garland, Yun Ju Christine Song, Chloe Wilson, Cathrin Rohleder, Catherine McHugh, F. Markus Leweke, Dagmar Koethe, Elizabeth M Scott & Ian B Hickie. (2022) Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial. BMJ Open 12:9, pages e056298.
Crossref
Crossref
Scott A. Wilke, Karen Lavi, Sujin Byeon, Kevin C. Donohue & Vikaas S. Sohal. (2022) Convergence of Clinically Relevant Manipulations on Dopamine-Regulated Prefrontal Activity Underlying Stress Coping Responses. Biological Psychiatry 91:9, pages 810-820.
Crossref
Crossref
Nicolas A Nuñez, Boney Joseph, Mehak Pahwa, Rakesh Kumar, Manuel Gardea Resendez, Larry J Prokop, Marin Veldic, Ashok Seshadri, Joanna M Biernacka, Mark A Frye, Zhen Wang & Balwinder Singh. (2022) Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. Journal of Affective Disorders 302, pages 385-400.
Crossref
Crossref
David S. KrollDavid S. Kroll. 2022. Caring for Patients with Depression in Primary Care. Caring for Patients with Depression in Primary Care
61
73
.
Christopher D. Bruno, Ahmed Elmokadem, Conrad Housand, Eric Burroughs Jordie, Christina R. Chow, Thomas P. Laughren & David J. Greenblatt. (2021) Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment. The Journal of Clinical Pharmacology 62:1, pages 55-65.
Crossref
Crossref
Irina Vladimirovna Dubatova, Lema Andreevich Antsyborov, Artur Fedorovich Kheigetian & Andrey Viktorovich Antsyborov. (2021) “Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists?. Interactive science:10 (65).
Crossref
Crossref
Alice Caldiroli, Enrico Capuzzi, Ilaria Tagliabue, Martina Capellazzi, Matteo Marcatili, Francesco Mucci, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli & Antonios Dakanalis. (2021) Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. International Journal of Molecular Sciences 22:23, pages 13070.
Crossref
Crossref
Filippo Cantù, Valentina Ciappolino, Paolo Enrico, Chiara Moltrasio, Giuseppe Delvecchio & Paolo Brambilla. (2021) Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression. Journal of Affective Disorders 280, pages 45-53.
Crossref
Crossref
Michele Fornaro, Domenico De Berardis, Annalisa Anastasia & Andrea Fusco. 2021. Major Depressive Disorder. Major Depressive Disorder
449
461
.
Muhammad Sheeraz Ahmad, Salma Batool, Arshad Islam, Ammara Jabeen, Azka Noureen, Sana Shamshad, Tayyaba Zainab, Maryam Shahid & Warda Ahmed. 2021. Biochemistry of Drug Resistance. Biochemistry of Drug Resistance
255
277
.
Piper A. Ranallo & Jessica D. Tenenbaum. 2021. Mental Health Informatics. Mental Health Informatics
1
30
.
Hiroyuki Fujiyama, Hiroko Sugawara, Teppei Kanno, Kazuhiro Kawahara, Hibiki Tanaka, Ryuji Fukuhara, Shuken Boku & Minoru Takebayashi. (2020) Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report. Psychiatry and Clinical Neurosciences 74:12, pages 666-667.
Crossref
Crossref
Daryl DeKarske, Gustavo Alva, Jason L. Aldred, Bruce Coate, Marc Cantillon, Lori Jacobi, Rene Nunez, James C. Norton & Victor Abler. (2020) An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression. Journal of Parkinson's Disease 10:4, pages 1751-1761.
Crossref
Crossref
Gin S. Malhi, Grace Morris, Erica Bell & Amber Hamilton. (2020) A New Paradigm for Achieving a Rapid Antidepressant Response. Drugs 80:8, pages 755-764.
Crossref
Crossref
Ayman Antoun Reyad, Eriny Girgis & Raafat Mishriky. (2020) Efficacy and safety of brexpiprazole in acute management of psychiatric disorders. International Clinical Psychopharmacology 35:3, pages 119-128.
Crossref
Crossref